- Home
- IMMX vs NTZ Comparison
IMMX vs NTZ Comparison
Compare IMMX & NTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- NTZ
- Stock Information
- Founded
- IMMX 2014
- NTZ 1959
- Country
- IMMX United States
- NTZ Italy
- Employees
- IMMX N/A
- NTZ N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- NTZ Home Furnishings
- Sector
- IMMX Health Care
- NTZ Consumer Discretionary
- Exchange
- IMMX Nasdaq
- NTZ Nasdaq
- Market Cap
- IMMX 61.1M
- NTZ 41.6M
- IPO Year
- IMMX 2021
- NTZ 1993
- Fundamental
- Price
- IMMX $2.55
- NTZ N/A
- Analyst Decision
- IMMX Strong Buy
- NTZ
- Analyst Count
- IMMX 1
- NTZ 0
- Target Price
- IMMX $7.00
- NTZ N/A
- AVG Volume (30 Days)
- IMMX 145.9K
- NTZ 1.2K
- Earning Date
- IMMX 08-11-2025
- NTZ 07-02-2025
- Dividend Yield
- IMMX N/A
- NTZ N/A
- EPS Growth
- IMMX N/A
- NTZ N/A
- EPS
- IMMX N/A
- NTZ N/A
- Revenue
- IMMX N/A
- NTZ $337,653,480.00
- Revenue This Year
- IMMX N/A
- NTZ N/A
- Revenue Next Year
- IMMX N/A
- NTZ N/A
- P/E Ratio
- IMMX N/A
- NTZ N/A
- Revenue Growth
- IMMX N/A
- NTZ N/A
- 52 Week Low
- IMMX $1.26
- NTZ $3.07
- 52 Week High
- IMMX $3.00
- NTZ $6.27
- Technical
- Relative Strength Index (RSI)
- IMMX 61.17
- NTZ 40.63
- Support Level
- IMMX $2.16
- NTZ $3.25
- Resistance Level
- IMMX $2.31
- NTZ $3.78
- Average True Range (ATR)
- IMMX 0.18
- NTZ 0.04
- MACD
- IMMX 0.00
- NTZ -0.01
- Stochastic Oscillator
- IMMX 92.59
- NTZ 30.30
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About NTZ Natuzzi S.p.A.
Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.